Amgen to Present at the 29th Annual JP Morgan Healthcare Conference

THOUSAND OAKS, Calif., Jan. 6, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) will present at the 29th Annual JP Morgan Global Healthcare Conference at 8:00 a.m. Pacific Time on Tuesday, Jan. 11, 2011, at the Westin St. Francis in San Francisco, Calif.  Amgen Chairman and CEO Kevin Sharer will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors.

About Amgen

Amgen discovers, develops, manufactures and delivers innovative human therapeutics.  A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient.  Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses.  With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives.  To learn more about our pioneering science and our vital medicines, visit www.amgen.com.

CONTACT: Amgen, Thousand Oaks

David Polk, 805-447-4613 (media)

Arvind Sood, 805-447-1060 (investors)



(Logo:  http://photos.prnewswire.com/prnh/20081015/AMGENLOGO)

SOURCE Amgen

Suggested Articles

Teva is reportedly going for a moonshot with a $15 billion drug offer to settle its opioid cases. It's a plan that might just work, one analyst said.

CSL has sued a former exec who its says stole thousands of key documents as he left for competitor Pharming.

Influential U.S. cost watchdog ICER gave its blessing to Johnson & Johnson and Amarin's CV drugs. But there's a big catch for both meds.